The future of antibiotics lies in combination treatments
With the fast emergence of antimicrobial resistance, what is the future for antibiotic therapies? Find out more in this interview with Anthony Coates (Helperby Therapeutics; London, UK) from Future Drug Discovery.
Antimicrobial resistance (AMR) is one of the greatest threats faced by modern medicine, with resistance of common bacteria at an epidemic level and the last of the penicillins being nearly obsolete in many countries, it is a key area of research in the field of drug discovery.
In a recent interview with Anthony Coates, Co-founder of the biopharmaceutical company Helperby Therapeutics (London, UK), we discuss the future for antibiotic therapies, why this is such an important field and how we could go about overcoming AMR.
Helperby works towards discovering and developing new antibiotic combinations, working alongside institutions to develop clinical trials and further pharmaceutical development. As well as being co-founder of the company, Coates is also a Professor of Medical Microbiology at St George's University (London, UK).
Coates A. The future of antibiotics lies in combination treatments. Future Drug Discovery. https://doi.org/doi/10.4155/fdd-2019-0012 (2019)